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ABSTRACT The prothoracicotropic hormone (PTTH) of
Drosophila melanogaster is a modulator of ecdysteroid (molting
hormone) synthesis and was isolated and characterized from
extracts of whole larvae ('4 3 105 larvae). The purification
protocol included delipidation, salt-extraction, heat treat-
ment, conventional column chromatography, and HPLC, and
yielded about 50 mg of pure hormone. Biological activity was
followed using a ring gland in vitro assay in which ecdysteroi-
dogenesis by control ring glands as measured by radioimmu-
noassay was compared with ring gland incubations containing
active fractions. The molecular weight of the purified PTTH
was 45 kDa and N-terminal amino acid sequence analysis
indicated that those analyzed sequences displayed no signif-
icant homology with known peptides or peptide hormones,
including PTTH from the silkmoth, Bombyx mori. Western
blot analysis indicated that the native form of Drosophila
PTTH was a single 66-kDa polypeptide with N-linked carbo-
hydrate chains and intrachain disulfide bonds. The purified
45-kDa peptide is the deglycosylated form, a result of glyco-
sidase activity present during preparation of the PTTH ex-
tract. The deglycosylated form shows heterogeneity, presum-
ably as a result of varying degrees of deglycosylation at the N
terminus.
Prothoracicotropic hormone (PTTH), produced by specific
neurosecretory cells (prothoracicotropes) in the insect brain,
controls the cyclical progress of insect molting by modulating
the synthesis of ecdysteroids (molting hormones) by the pro-
thoracic glands via a second messenger transduction cascade
(1, 2). Upon reaching its target tissue the ecdysone is hydroxy-
lated to 20-hydroxyecdysone, the principal insect molting
hormone (2).
Since Kopeć (3) suggested that the larval brain of the gypsy
moth,Lymantria dispar, secretes a factor necessary for molting,
attempts have been made to purify and characterize the ‘‘brain
hormone’’ (subsequently called PTTH). Available knowledge
of the identity and molecular structure of PTTH is based
largely on experiments with the silkworm, Bombyx mori, and to
a lesser extent, with the tobacco hornworm,Manduca sexta (1,
2, 4, 5). In the former case, a 30-kDa PTTH has been purified
and cloned (6, 7), whereas in the case ofManduca, progress has
been made (8) but the complete sequence remains elusive (9,
10). The prothoracicotropes in the Lepidoptera appear to be
two large, lateral neurosecretory cells in each brain hemi-
sphere (11–13).
PTTH is the primary signal carrier for initiating the molting
cycle, and it would be most useful if the power of genetic
analysis could be employed in studies of how environmental
cues elicit PTTH synthesis and release, how PTTH brings
about enhanced ecdysteroidogenesis, how PTTH synthesis and
release are regulated, etc. However, the purification and
characterization of Drosophila PTTH have not been attained,
perhaps because of the insect’s small size and the fact that the
larval ecdysteroid-producing gland is part of a complex, the
ring gland (14), rather than existing as an individual structure
(2). The ability of neural extracts to stimulate ecdysteroid
synthesis by the larval ring glands in vitro provided a reliable
physiological assay for the Drosophila PTTH (14), leading to
this report on the purification and characterization of PTTH
from Drosophila melanogaster.
MATERIALS AND METHODS
Reagents. Column chromatographic and other chemicals
were obtained from Sigma. Radioactive [23,24-3H]ecdysone
(specific activity: 47.3 Ci/mmol; 1 Ci5 37 GBq) was purchased
from New England Nuclear. The anti-ecdysone antibody
(DUL-I) used in the radioimmunoassay (RIA) was from
Trifolio-M (Lahnau, Germany), alkaline phosphatase-
conjugated anti-mouse IgG was from Promega, and endogly-
cosidase was from Boehringer Mannheim.
Animals. The Oregon-R (Or-R) wild-type strain of D.
melanogaster was reared in uncrowded conditions in a plastic
cage on standard medium containing corn meal, sugar, agar,
yeast, and propionic acid as mold inhibitor. The animals were
maintained at 70–80% humidity, 23 6 18C under a photope-
riodic regimen (12-hr light/12-hr dark). Synchronization of
developmental stage was achieved according to published
methods (15). Third instar larvae were collected as starting
material for PTTH purification and were stored at2708C until
use.
In Vitro Assay of PTTH Activity. PTTH activity recovered
from each purification step was assessed using the in vitro ring
gland assay described (16). This assay uses five glands from
wandering third instar larvae as a control (2PTTH) and five
glands as the experimental (1PTTH) group with the degree
of gland activation expressed as an activation ratio (Ar) defined
as the amount of ecdysone synthesized by the experimental
glands divided by that synthesized by control glands. Ring
glands were dissected out and incubated for 2 hr in 20 ml of
Grace’s medium (GIBCO) at 248C under high humidity in the
dark. Each incubation was terminated by removing the culture
medium for assay of its ecdysone content by modification of
previously described RIA procedures (17, 18). The labeled
ligand was [23,24-3H]ecdysone and unlabeled ecdysone was
used as the competing ligand. All RIA analyses were repeated
at least six times.
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Preparation of Larval Extracts andHeat Treatment. Larvae
('43 105, approximate wet weight 0.8 kg) were homogenized
in 3 vol of cold acetone containing 1 mM phenylmethylsulfonyl
f luoride (PMSF) and 100 mM L-1-tosylamido-2-phenylethyl
chloromethyl ketone (TPCK) using a Waring blender at 48C.
The homogenate was centrifuged at 60003 g for 10 min at 48C,
and the yellow supernatant was discarded. PTTH activity was
recovered successfully from the acetone powder after it was
solubilized with 5 vol of 2% NaCl containing 1 mM PMSF and
100 mM TPCK (pH 6.8). After each extraction, insoluble
material was removed by centrifugation and subsequent heat
treatment (958C for 3 min with shaking). The supernatant after
heat treatment was subjected to acetone precipitation and the
precipitate assayed for PTTH activity after being dissolved in
0.05 M TriszHCl (pH 7.8) and dialyzed against three changes
of 10 vol of buffer.
Q-Sepharose Column Chromatography. The concentrated
protein solution was loaded onto a Q-Sepharose column (303
250 mm) equilibrated with 0.05 M TriszHCl buffer (pH 7.8),
and fractions were eluted with the same buffer and assayed for
PTTH activity. All buffers used for chromatographic purifi-
cation contained protease inhibitors (1 mMPMSF and 100mM
TPCK).
S-Sepharose Column Chromatography. Following concen-
tration and dialysis, the active fractions from the Q-Sepharose
column were applied to an S-Sepharose column (25 mm3 150
mm), which was developed with a linear gradient of NaCl
(0–0.4 M) in 0.05 M sodium acetate buffer (pH 5.6) at a flow
rate of 90 ml/hr. Fractions eluted from the columns were
monitored routinely by optical absorption at 280 nm and
assayed for PTTH activity.
C18 Reverse-Phase HPLC (RPHPLC). All fractions with
PTTH activity from the previous step were pooled, concen-
trated, and lyophilized. The lyophilized sample (4 mg) was
dissolved in 2 ml H2O containing 1 mM PMSF and 100 mM
TPCK and applied to a 4.6 3 300 mm C18 column (Vydac,
Hesperia, CA), equilibrated with 20% acetonitrile. Elution
used a linear gradient of 20–40% acetonitrile in 0.05% trif-
luoroacetic acid (TFA) for 60 min at a flow rate of 1 ml/min.
Fractions were collected and bioassayed.
Superdex G-75 Gel Filtration. After lyophilization, the
HPLC active fractions were dissolved in 0.05 M TriszHCl
buffer (pH 7.8) and applied to a Superdex G-75 gel-filtration
column (Superfine, 15 3 610 mm) that has been equilibrated
with the same TriszHCl buffer at a flow rate of 60 ml/hr.
Two-milliliter fractions were collected and bioassayed.
SDS/PAGE. SDS/PAGE was carried out as described (19).
Aliquots of various purified PTTH fractions were analyzed
after treatment with or without reducing reagent (5% 2-mer-
captoethanol in the sample buffer) in a 1-mm thick, 12%
acrylamide gel. Gels were stained with Coomassie brilliant
blue R-250.
Amino Acid Sequence Analysis. Aliquots of PTTH purified
as described above were subjected to SDS/PAGE after treat-
ment with a reducing agent and transferred to a polyvinylidine
dif luoride (PVDF) membrane (Bio-Rad). The membrane was
stained with Ponceau-S and the stained bands were cut out for
sequence analysis. Amino acid sequence analysis was per-
formed using HPLC (MilliGen) in tandem with a phenylthio-
hydantoin amino acid analyzer (MilliGen 6600B).
Preparation of Antiserum Against Purified 45-kDa PTTH.
Mouse polyclonal antiserum against the purified PTTH was
obtained as described (20). A male C57Br/6J mouse was
immunized by intramuscular injection of purified PTTH (10
mg) in complete Freund’s adjuvant and by three boosters of the
purified PTTH (7 mg) in complete Freund’s adjuvant at
1-week intervals. Ten days after the last injection, serum was
obtained from the mouse and stored at 2208C until use.
Western Blot Analysis. Third instar larvae were homoge-
nized in 300 ml of 2% NaCl (pH 6.8) containing 2 mM PMSF
and 200 mM TPCK in an Eppendorff tube and sonicated
briefly. The homogenate was heated in boiling water for 3 min,
cooled rapidly and centrifuged at 24,000 3 g for 30 min.
Samples were analyzed by PAGE (12% polyacrylamide slab
gel) and then electrophoretically transferred to a PVDF
membrane (21, 22). The membrane was blocked with 2%
bovine serum albumin in TBST buffer (10 mM TriszHCl, pH
8.0/150 mM NaCl/0.1% Tween 20) for 1 hr and incubated with
a 1:10,000 dilution of PTTH antiserum for 1 hr at room
temperature. After washing with TBST, the membrane was
incubated with a 1:5000 dilution of alkaline phosphatase-
conjugated anti-mouse IgG serum (Promega) for 1 hr. The
color reaction was carried out using 5-bromo-4-chloro-3-
indolylphosphate and nitroblue tetrazolium as substrates in
alkaline phosphatase buffer (100 mM TriszHCl, pH 9.5/100
mM NaCl/5 mM MgCl2).
Enzyme Digestion of Intact PTTH with Glycosidase. Third
instar larval extracts and brain extracts were dissolved in
distilled water containing 1 mM PMSF and 100 mMTPCK and
103 reaction buffer [50 mM sodium phosphate buffer (pH
7.2)]. After the addition of N-glycosidase F or O-glycosidase,
the reaction mixtures were incubated at 378C for 1 hr and then
subjected to immunoblotting using PTTH antiserum.
Immunohistochemistry. Whole-mount immunohistochem-
istry was performed by modifying a previously published
method (12) and using the antiserum at a dilution of 1:1000
with a 1:500 dilution of alkaline phosphatase-conjugated anti-
mouse IgG goat serum.
RESULTS
Purification of 45-kDa PTTH. The purification protocol
consisted of seven steps including delipidation, salt-extraction,
heat treatment, conventional column chromatography and
HPLC. The ring gland bioassay was used at each step. An
'80-fold purification from the heat treatment step was at-
tained yielding '50 mg of the putative hormone with a
recovery of 1.2% (Table 1). Substances such as endogenous
ecdysteroids in the crude extracts that could interfere with the
bioassay were removed in the acetone powder step. The
specific activity of the crude extracts prior to heat treatment
could not be determined due to an endogenous contaminant













Acetone powder 1.72 3 105 — — — — —
2% NaCl extract 1.60 3 103 — — — — —
Heat treatment 340.00 8.0 125 42,500 100.00 1.00
Q-Sepharose 31.00 4.1 244 7,600 17.80 1.95
S-Sepharose 4.00 0.8 1,250 5,000 11.80 10.00
HPLC 1.00 0.5 2,000 2,000 4.71 16.00
Superdex G-75 0.05 0.1 10,000 500 1.20 80.00
Third instar larvae of D. melanogaster, 4 3 105 (0.8 kg) were used as starting material.
*One unit (i.e., critical dose) corresponds to the amount of hormone that is required to increase the ecdysone Ar from 1 to 2 during a 2-hr incubation.
Biochemistry: Kim et al. Proc. Natl. Acad. Sci. USA 94 (1997) 1131
in the sample that interfered with the in vitro assay. Therefore,
the activity of the supernatant after heat treatment was set at
100%.
The supernatant after heat treatment was subjected to
anion-exchange chromatography using Q-Sepharose. PTTH
activity was detected in the ‘‘f lowthrough’’ fraction from the
column, but not in the bound fractions. After concentration
and dialysis, the unadsorbed fraction from the Q-Sepharose
was applied to a cation-exchange chromatography using S-
Sepharose and eluted with a salt gradient. PTTH activity
eluted in a peak between 0.12–0.16 M NaCl (Fig. 1A). The
resulting purification in this step was about 10-fold, with
essentially full recovery of PTTH activity. The active fractions
from S-Sepharose chromatography were lyophilized and ap-
plied to a RPHPLC C18 column, and PTTH activity was
eluted with 26–29% acetonitrile containing 0.05% TFA (Fig.
1B). Total PTTH activity was 2000 units and was active at a
dose of 0.5 mg in the ring gland in vitro assay. After further
purification by HPLC in which peaks 7–10 showed biological
activity, the HPLC active fractions were lyophilized and then
applied to a Superdex G-75 gel filtration column (Fig. 1C). The
in vitro assay revealed that fractions 27–31 were active and
yielded 50 mg of material with an overall recovery of 1.2%. To
assess its purity, the fractions with PTTH activity were pooled
and subjected to SDS/PAGE (Fig. 2A). The PTTH showed a
broad band under nonreducing conditions corresponding to 45
kDa. Under reducing conditions, the 45-kDa band was no
longer evident and three sharp bands (40, 38, and 33 kDa) and
a few smaller ones (,10 kDa) were detected (data not shown).
Amino Acid Sequence Analysis. To determine the N-
terminal amino acid sequence needed to design a primer for
gene cloning, the reduced peptide fragments were prepared
and analyzed as described in Materials and Methods. Amino
acid sequence analysis revealed that 21 amino acid residues
could be detected in each of the two A and B fragments (Fig.
2B). The size of each sequenced fragment is about 2310 Da. If
both the 38- and 33-kDa fragments were cut at the N-terminal
end, there would be no overlapping of the sequences. If the cut
occurred within 2500 Da of the N terminus there also would
be no overlapping of the sequence. Although two smaller
fragments (,10 kDa) were subjected to amino acid sequence
analysis, no amino acid residue signals were detected—i.e., the
N termini were blocked.
In Vitro Activation of Ring Gland by Purified PTTH. The
purified 45-kDa PTTH elicited a significant, dose-dependent
increase in ecdysteroid secretion by ring glands in vitro. Serial
dilutions of purified 45-kDa PTTH evoked a range of re-
sponses that approximates a saturation curve when assayed on
ring glands (Fig. 3A). The purified 45-kDa moiety stimulated
ecdysone synthesis and secretion at a dose of 0.05 mg, whereas
0.2 mg elicited maximal activity. When the in vitro assay was
performed with PTTH fractions obtained during the purifi-
cation processes, the relatively concentrated protein inhibited
ecdysone synthesis by the ring gland in some cases, somewhat
similar to what has been reported for Manduca sexta PTTH
(23). However, when purified 45-kDa PTTH was assayed at a
high concentration, no such inhibition effect was noted (data
not shown).
Immunoblot Analysis. Using the mouse antiserum raised
against the purified 45-kDa PTTH, Western blot analysis
revealed the high specificity of the antibody for the 45-kDa
PTTH, as well as the reduced fragments (data not shown).
FIG. 1. Chromatographic separations of PTTH. Solid line denotes
gradient, solid circles PTTH activity recovered, and broken line
absorbance. (A) Ion-exchange chromatography using an S-Sepharose
column. The column was eluted with a linear gradient of 0–0.4MNaCl
in a 0.05 M sodium acetate buffer (pH 5.6). PTTH activity was
recovered from fractions eluted with a gradient of 0.12–0.16 M NaCl.
(B) RPHPLC using a C18 column. PTTH was eluted with a linear
gradient of 20–40% acetonitrile in 0.05% TFA for 60 min at 258C at
a flow rate of 1 ml/min. (C) Gel filtration chromatography using a
Superdex G-75 column. The 45-kDa PTTH was eluted in fractions
27–31, each fraction being 2 ml. First arrow denotes void volume,
second arrow the fraction where bovine serum albumin (66.8 kDa)
eluted during column calibration, third arrow the fraction where
carbonic anhydrase (29 kDa) eluted during column calibration, and
fourth arrow where cytochrome c (12.4 kDa) eluted during column
calibration. Activation ratio (Ar) 5 The quantity of ecdysone synthe-
sized by the ring glands in Grace’s medium with PTTH/The quantity
of ecdysone synthesized by the ring glands in Grace’s medium alone
(control)
FIG. 2. (A) SDS/PAGE analysis of the purified 45-kDa PTTH
under both nonreducing and reducing (2-mercaptoethanol) condi-
tions. Lanes: M, molecular mass markers; 1, 1.0 mg of pure PTTH
under nonreducing conditions; 2, 3.0 mg of pure PTTH under reducing
conditions. To conserve space the figure was cropped and the smaller
fragments—e.g., 10 kDa are not shown. (B) N-terminal amino acid
sequence of two reduced PTTH fragments, A and B.
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When whole body larval extracts were reduced with 2-mer-
captoethanol and subjected to electrophoresis under normal or
reducing conditions, a major band was noted in crude extracts
at 66 kDa, as well as several minor bands. When the crude
larval extract without protease inhibitors was incubated at
378C for 1 hr, the 66-kDa component was no longer evident
(data not shown).
To examine the specificity of the anti-PTTH serum against
the 45-kDa PTTH, serial dilutions of anti-PTTH antiserum
were incubated with the latter, and after incubation the sample
was subjected to the ecdysone RIA. The data showed that the
anti-PTTH antiserum inhibited the activity of the purified
PTTH in a dose-dependent manner (Fig. 3B). PTTH activity
was inhibited at a dose of 0.2 ml of antiserum, and maximal
inhibition was observed at a dose of 2.0 ml. These results
indicate that the antibody recognizes an epitope of the purified
45-kDa PTTH essential for biological activity.
Characterization of the Native PTTH–Glycoside. To deter-
mine why both the purified 45-kDa PTTH and the prominent
66-kDa component present in larval extracts reacted to the
antibody during Western blot analysis, the possibility of a
carbohydrate moiety was examined. The mobility of the 66-
kDa component of larval extracts was not affected by reducing
conditions (Fig. 4, lanes 1) and when the sample was incubated
with N-glycosidase under nonreducing conditions, a new 45-
kDa component appeared along with the 66-kDa band (Fig.
4A, lane 2). On the other hand, when the N-glycosidase
digested sample was reduced, the 45-kDa band was no longer
evident but a 40-kDa band appeared (Fig. 4B, lane 2). The
above events were not observed when the 66-kDa peptide was
incubated with O-glycosidase (Fig. 4, lanes 3). The band below
the 66-kDa band (Fig. 4A, lanes 1 and 3) appeared only
intermittently and is probably a partially degraded product of
the 66-kDa band.
These results suggest that the Drosophila native PTTH is a
66-kDa peptide containing an N-linked carbohydrate moiety,
and that the purified 45-kDa molecule is the deglycosylated
form of PTTH. Furthermore, the native 66-kDa form appears
to be a single polypeptide with intrachain disulfide bonds.
Because the carbohydrate portion of the 66-kDa PTTH was
not completely digested by an excess amount of N-glycosidase,
the larval extracts probably contain high levels of glycoprotein
as well as the previously mentioned unknown substances that
interfere with the RIA.
To ensure that the identified PTTH is indeed from the brain
of Drosophila, extracts of third instar larval brains were
analyzed by immunoblotting under the same conditions as in
Fig. 4. In both the presence or absence of protease inhibitors,
a major 66-kDa band was immunostained (Fig. 5, lanes 2 and
3). However, when brain extracts were incubated at 378C for
1 hr without protease inhibitor, the 66-kDa peptide disap-
peared (Fig. 5, lane 1). When the sample was digested with
N-glycosidase, the 66-kDa band was replaced by the 45-kDa
band (Fig. 5, lane 4). When the digested sample was reduced,
the 45-kDa band gave rise to 40- and 33-kDa peptides (Fig. 5,
lane 5). These 40- and 33-kDa components appear to be
identical to the reduced fragments of the purified 45-kDa
PTTH. These data show that PTTH does exist in the Dro-
sophila brain and indicate that the native PTTH is a 66-kDa
glycoprotein containing N-linked carbohydrate chains.
Effects of Protease and Deglycosidase on PTTH Stability.
To investigate further the protease effect on the PTTH of
larval extracts, these larval extracts were incubated with or
without protease inhibitor at 378C for various periods (0–24
hr) and then subjected to SDS/PAGE and immunoblot analysis
(data not shown). An immunoreactive 66-kDa band decreased
in intensity as the incubation time increased (0–40 min) in the
absence of protease inhibitors, and was no longer observed
after 60 min. These results indicate that the PTTH is degraded
FIG. 3. Effect of antiserum on PTTH activity in the in vitro assay.
(A) Dose-dependent effect of the purified 45-kDa PTTH on ecdysone
secretion by the ring glands in vitro. Each datum point represents the
mean (6SEM) of four separate determinations. (B) Inhibition of the
activity of purified PTTH by the anti-PTTH antiserum. Various doses
of anti-PTTH anti-serum and purified PTTH (0.5 mg) were incubated
together and the mixture was then assayed using the ring gland in vitro
assay as in A.
FIG. 4. Characterization of the native PTTH glycopeptide. Third
instar larval extract was incubated with endoglycosidase for 1 hr at
378C, and the samples were then subjected to SDS/PAGE under
nonreducing (A) or reducing (B) conditions followed by immunoblot-
ting. Lanes: 1, incubation medium contained protease inhibitors (2
mM PMSF and 200 mM TPCK); 2, incubation medium contained
N-glycosidase (3 units); 3, incubation medium contained O-
glycosidase (0.75 unit).
FIG. 5. Western blot analysis of PTTH in brain extracts using
anti-PTTH antiserum. Protein (10 mg) extracted from brains of third
instar larvae was separated by SDS/PAGE and subjected to immuno-
blotting. Lanes: 1, extract was incubated at 378C for 1 hr without
protease inhibitors before Western blot analysis; 2, extract analyzed in
absence of protease inhibitors; 3, brain extract analyzed in the presence
of protease inhibitors (2 mMPMSF and 200 mMTPCK); 4, extract was
treated with N-glycosidase at 378C for 1 hr under nonreducing
conditions before analysis; 5, extract was treated with N-glycosidase at
378C for 1 hr under reducing conditions.
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during sample preparation by an endogenous proteinase(s) if
the latter are not inhibited. When larval extracts were incu-
bated in the presence of protease inhibitors, the 66-kDa
peptide (and a 60-kDa band) stained intensely (data not
shown). After a 3 hr incubation, the 60-kDa moiety stained
more intensely than the 66-kDa PTTH and a broad band of
about 45-kDa appeared. By 12 hr, both the 66- and 60-kDa
bands were absent but the broad band(s) of about 45-kDa
persisted. Under reducing conditions, a 33-kDa band ap-
peared. These results confirm the conclusion that the 66-kDa
PTTH is digested by endogenous deglycosidase during the
preparation of larval extracts and that the heterogeneous
forms of the 45-kDa PTTH noted may result from the partial
digestion of the carbohydrate chain. These results also suggest
strongly that purified 45-kDa PTTH is the deglycosylated form
of the native 66-kDa PTTH.
Activity Assay of the Degraded PTTH Fragment. To deter-
mine if degraded PTTH retains activity, larval extracts were
incubated with or without protease inhibitor (PMSF or TPCK)
at 378C for 24 hr and then divided into two samples. One was
subjected to immunoblotting and the other was bioassayed via
the in vitro ring gland RIA paradigm. It should be noted that
PMSF is more effective than TPCK in reducing endogenous
proteolytic activity and each inhibitor yields its own unique
degradation pattern. In the absence of 2-mercaptoethanol and
with PMSF, degradation does not proceed past the 45-kDa
band, but in the presence of 2-mercaptoethanol and PMSF the
33-kDa band appears. With TPCK the 45-kDa band was not
seen and degradation proceeded to 22-kDa fragments in the
presence or absence of 2-mercaptoethanol. The 22-kDa frag-
ments showed no PTTH activity upon assay, but the 45-kDa
peptide did stimulate ecdysteroid synthesis and secretion as did
the native 66-kDa PTTH. These data reveal that PMSF is a
more effective protease inhibitor than TPCK in this system. A
combination of both inhibitors was used in subsequent exper-
iments. The results of this study suggest that the deglycosylated
PTTH is functionally indistinguishable from the native PTTH
and that the glycosyl group of the native form has another role,
perhaps as a deterrent to proteolytic degradation.
Immunoblot Analysis of the Developmental Expression of
PTTH. To examine possible developmental changes in PTTH
content, extracts from several developmental stages were
analyzed by SDS/PAGE under nonreducing conditions fol-
lowed by immunoblotting. The 66-kDa PTTH was first de-
tected in third instar larvae and reached its maximal level at
this stage (Fig. 6). The PTTH level then decreased gradually
but was detectable even in the adult. PTTH was not detected
in embryos or in extracts of first and second instar larvae.
These data are in accord with the pattern of ecdysteroid
synthesis during development (24).
Cross-Reactivity of Anti-Drosophila PTTH Antiserum with
Brain Extracts of Bombyx mori. To examine interspecific
PTTH relationships between two insect orders, Lepidoptera
and Diptera, brain extracts from fifth instar larvae of Bombyx
mori and third instar larvae of Drosophila were analyzed by
immunoblotting using the anti-PTTH serum. Western blot
analysis revealed a positive signal in the brain of Drosophila,
but not in the brain of Bombyx mori (data not shown).
Immunohistochemical Localization of PTTH. A pair of
small dorso–medial neurosecretory cells in the brains of third
instar larvae were highly immunoreactive to the anti-PTTH
antiserum (data not shown). Serial sections suggested that a
pair of immunoreactive tracks extended from the center of the
medial region of the brain hemisphere to the surface that is
connected to the ring gland. Whole mount immunohistochem-
istry against Drosophila third instar larval brain, ventral gan-
glion, and ring gland complexes was also performed, and only
the central nervous system showed immunoaffinity to the
antibody preparation. In general, the data were similar to that
generated using Bombyx anti-PTTH antibody (25). No immu-
noreactivity was detected in the control preparations that were
treated with preimmune mouse serum.
DISCUSSION
Approximately 50 mg of a Drosophila 45-kDa peptide with
PTTH activity were obtained from 43 105 (0.8 kg) whole body
extracts of third instar larvae using a seven-step procedure. In
the case of the only other PTTH purified and characterized,
that of the silkworm Bombyx mori, 15 mg of pure PTTH was
obtained from 5 3 105 heads (3.7 kg wet weight) (5). The
weight of the starting material was about 4.5 times that of the
Drosophilamaterial, but about three times as much PTTH was
finally obtained from the fly larval extracts as that from
Bombyx adult heads. Conventional liquid chromatography was
not sufficient to isolate the pure hormone since the elution
patterns of PTTH activity with conventional chromatography
showed that the 45-kDamoiety was highly heterogeneous. This
is not surprising, however, because such heterogeneity has
been found for other insect peptide hormones (5, 12, 23, 26).
However, the use of RPHPLC and the final procedure of gel
filtration served to remove small contaminating molecules.
The purified 45-kDa peptide stimulated ecdysone synthesis
and secretion by ring glands in vitro at a dose of 50 ng. Maximal
activity was obtained with a dose of 200 ng, this amount being
comparable to the lowest effective dose of Bombyx PTTH on
the Bombyx prothoracic glands (5, 7), and this '10 nM
concentration is in agreement with the physiological doses of
other insect neurohormones as well.
When subjected to SDS/PAGE under reducing conditions,
the sum of the apparent molecular weights of the reduced
fragments exceeded the molecular weight of the purified
45-kDa peptide, as did that of the Bombyx PTTH (5). Amino
acid sequence analysis revealed several overlapping signals for
the 45-kDa peptide, but each signal was for a corresponding
fragment under reducing conditions. These data suggest that
the purified deglycosylated PTTH exists as a single 45-kDa
polypeptide that was cleaved at a minimum of three different
sites by an endoprotease during the purification procedure.
These fragments are probably held together by intradisulfide
bonds.
It has been reported that both Bombyx PTTH andManduca
PTTH are homodimers (5, 10, 26) and that Bombyx PTTH
probably contains a carbohydrate chain bound to an aspara-
gine at position 41 of the peptide, as deduced from the cDNA
sequence (5, 27). However, the apparent native PTTH of
Drosophila is a monomeric 66-kDa glycoprotein. The mobility
of this protein band during PAGE was not altered under
reducing conditions. In addition, the putative glycosylation of
PTTH was tested by removing any N-linked oligosaccharide
FIG. 6. Developmental expression of the 66-kDa PTTH. Protein
extracts (28 mg) from each stage were subjected to SDS/12% PAGE,
followed by immunoblotting using the anti-PTTH antiserum. Lanes:
1, eggs; 2, first instar larvae; 3, second instar larvae; 4, third instar
larvae; 5, pupae; 6, adults.
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with a specific endoglycosidase and determining the effect on
size and heterogeneity. The data revealed that the major
66-kDa band as well as several minor, smaller bands were
shifted to the 45-kDa band under nonreducing conditions, a
result consistent with deglycosylation of the 66-kDa moiety.
These data indicate that the Drosophila PTTH is a glycopro-
tein containing N-linked carbohydrate chains, and this possi-
bility is supported by the observation that the incubation of
larval extracts with protease inhibitors for 6 hr resulted in the
presence of only 45-kDa components. These heterogeneous
45-kDa ‘‘isoforms’’ remained intact until the incubation time
was extended to 24 hr. The 45-kDa peptides were subsequently
converted to a 33-kDa component under reducing conditions.
The data support the hypothesis that the PTTH of Drosophila
is a 66-kDa glycoprotein containing N-linked carbohydrate
chains and intradisulfide bonds. It is likely that the larval
extracts contain endoglycosidases, and the 45-kDa PTTH
variants arose due to different degrees of carbohydrate chain
cleavage resulting in different shapes and thus apparent mul-
tiple molecular weights.
It is also evident that the PTTH can undergo proteolysis
during the purification process due to the presence of endog-
enous proteases, since the 66-kDa PTTH disappeared within
1 hr after incubation at 378C in the absence of protease
inhibitors. The effect of protease inhibitors on the degradation
of PTTH as an indicator of overall proteolytic suppression was
analyzed, and PMSF appears to be the most effective.
In many glycoproteins, the carbohydrate moiety endows the
polypeptide with important physical characteristics such as
conformational stability, protease resistance, charge, and wa-
ter binding capacity (28). However, in the case of the Dro-
sophila PTTH, the glycosyl group is not requisite for biological
activity since the 45-kDa peptide was functionally indistin-
guishable from the native form, insofar as ring gland stimu-
lation was concerned. This is also true of the Bombyx PTTH
(5). Therefore, the glycosyl group may serve only as a guardian
against protease activity and perhaps aid in the stabilization of
the structure.
Previously, two smaller peptides were identified as candi-
dates for the Drosophila PTTH, and weak PTTH activity was
associated with a larger peptide (29). This reduced activity may
result from the absence of protease inhibitors in the larval
extract. In this study, lower molecular weight moieties with
PTTH activity were not noted, perhaps because of their
removal during the initial stages of purification or because they
are degradative products of the 66-kDa PTTH.
Insect postembryonic development is initiated and coordi-
nated by the precise temporal release of PTTH that is syn-
thesized by specific neurosecretory cells in the insect brain and
released from a neurohemal organ (2, 4, 11–13). In the case of
Drosophila, PTTH expression was maximal in third instar
larvae and decreased gradually throughout pupal–adult devel-
opment. At the adult stage, it was detected, albeit at a low level,
consistent with observations on the Bombyx PTTH. The
prothoracic gland portion of the ring gland undergoes degen-
eration and cell death during adult development and is absent
in adults (14), so that the adult ‘‘PTTH’’ may play a role
separate from the stimulation of ecdysteroidogenesis in the
adult f ly, as it may in the adult moth.
Although the immunocytochemical analysis using the
PTTH antibody is not yet complete, positive signals were
observed in the posterior–lateral area of the protocerebrum.
However, signals were also observed in other regions of the
brain, perhaps due to the transit of axonal tracts emanating
from the lateral cell bodies. In general, the picture resembled
that observed in the Drosophila brain when Bombyx antibody
was used as the probe (25). The reason for this similarity is
presently unknown.
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3. Kopeć, S. (1922) Biol. Bull. 42, 323–342.
4. Bollenbacher, W. E. & Granger, N. A. (1985) in Comprehensive
Insect Physiology, Biochemistry and Pharmacology, eds. Kerkut,
G. A. & Gilbert, L. I. (Pergamon, Oxford), Vol. 7, pp. 109–151.
5. Ishizaki, H. & Suzuki, A. (1992) Prog. Brain Res. 92, 1–14.
6. Suzuki, A., Nagasawa, H., Kataoka, H., Hori, Y., Isogai, A.,
Tamura, S., Guo, F., Zhong, X., Ishizaki, H., Fujishita, M. &
Mizoguchi, A. (1982) Agric. Biol. Chem. 46, 1107–1109.
7. Kawakami, A., Kataoka, H., Oka, T., Mizoguchi, A., Kimura-
Kawakami, M., Adachi, T., Iwamai, M., Nagasawa, H., Suzuki, A.
& Ishizaki, H. (1990) Science 247, 1333–1335.
8. Bollenbacher, W. E., Katahira, E. J., O’Brien, M., Gilbert, L. I.,
Thomas, M. K., Agui, N. & Baumhover, A. H. (1984) Science 224,
1243–1245.
9. Muelheisen, D. P., Gray, R. S., Katahira, E. J., Thomas, M. K. &
Bollenbacher, W. E. (1993) Peptides 14, 531–541.
10. Muelheisen, D. P., Katahira, E. J., Gray, R. S. & Bollenbacher,
W. E. (1994) Experientia 50, 159–163.
11. Mizoguchi, A., Oka, T., Kataoka, H., Nagasawa, H., Suzuki, A.
& Ishizaki, H. (1990) Dev. Growth Differ. 32, 591–598.
12. O’Brien, M. A., Katahira, E. J., Hanagan, T. R., Arnold, L. W.,
Haughton, G. & Bollenbacher, W. E. (1988) J. Neurosci. 8,
5840–5843.
13. Dai, J.-D., Mizoguchi, A. & Gilbert, L. I. (1994) Inverteb. Reprod.
Dev. 26, 187–196.
14. Dai, J.-D. & Gilbert, L. I. (1991) Dev. Biol. 144, 309–326.
15. Ashburner, M. & Tompson, J. N. (1978) The Genetics and Biology
of Drosophila (Academic, London).
16. Henrich, V. C., Pak, M. D. & Gilbert, L. I. (1987) J. Comp.
Physiol. B. 157, 543–549.
17. Warren, J. T. & Gilbert, L. I. (1986) Insect Biochem. 16, 65–82.
18. Reum, L. & Koolman, J. (1989) in Ecdysone: From Chemistry to
Mode of Action, ed. Koolman, J. (Thieme, Stuttgart), pp. 131–143.
19. Laemmli, U. K. (1970) Nature (London) 227, 680–685.
20. Harlow, E. & Lane, D. (1988) in Antibodies: A Laboratory
Manual, eds. Harlow, E. & Lane, D. (Cold Spring Harbor Lab.
Press, Plainview, NY), pp. 53–138.
21. Towbin, H., Staehelin, T. & Gordon, J. (1979) Proc. Natl. Acad.
Sci. USA 76, 4350–4354.
22. Burnette, W. N. (1981) Anal. Biochem. 112, 195–203.
23. Kingan, T. G. (1981) Life Sci. 28, 2585–2594.
24. Hodgetts, R. B., Sage, B. & O’Connor, J. D. (1977) Dev. Biol. 60,
310–317.
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